- Home
- COCH vs ALLK Comparison
COCH vs ALLK Comparison
Compare COCH & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- ALLK
- Stock Information
- Founded
- COCH 1995
- ALLK 2012
- Country
- COCH United States
- ALLK United States
- Employees
- COCH N/A
- ALLK N/A
- Industry
- COCH Blank Checks
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- ALLK Health Care
- Exchange
- COCH Nasdaq
- ALLK Nasdaq
- Market Cap
- COCH 64.4M
- ALLK 58.0M
- IPO Year
- COCH N/A
- ALLK 2018
- Fundamental
- Price
- COCH $2.08
- ALLK $1.21
- Analyst Decision
- COCH Strong Buy
- ALLK Hold
- Analyst Count
- COCH 4
- ALLK 5
- Target Price
- COCH $7.92
- ALLK $1.67
- AVG Volume (30 Days)
- COCH 669.9K
- ALLK 1.3M
- Earning Date
- COCH 11-14-2024
- ALLK 11-06-2024
- Dividend Yield
- COCH N/A
- ALLK N/A
- EPS Growth
- COCH N/A
- ALLK N/A
- EPS
- COCH N/A
- ALLK N/A
- Revenue
- COCH $302,000.00
- ALLK N/A
- Revenue This Year
- COCH N/A
- ALLK N/A
- Revenue Next Year
- COCH $17.09
- ALLK N/A
- P/E Ratio
- COCH N/A
- ALLK N/A
- Revenue Growth
- COCH 38.53
- ALLK N/A
- 52 Week Low
- COCH $0.75
- ALLK $0.54
- 52 Week High
- COCH $11.46
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- COCH 34.73
- ALLK 58.14
- Support Level
- COCH $1.88
- ALLK $1.25
- Resistance Level
- COCH $2.28
- ALLK $1.56
- Average True Range (ATR)
- COCH 0.28
- ALLK 0.13
- MACD
- COCH -0.02
- ALLK -0.01
- Stochastic Oscillator
- COCH 20.44
- ALLK 28.95
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.